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Abstract Epigenetics represents a phenomenon of altered
heritable phenotypic expression of genetic information
occurring without changes in DNA sequence. Epigenetic
modiﬁcations control embryonic development, differenti-
ation and stem cell (re)programming. These modiﬁcations
can be affected by exogenous stimuli (e.g., diabetic milieu,
smoking) and oftentimes culminate in disease initiation.
DNA methylation has been studied extensively and repre-
sents a well-understood epigenetic mechanism. During this
process cytosine residues preceding a guanosine in the
DNA sequence are methylated. CpG-islands are short-
interspersed DNA sequences with clusters of CG sequen-
ces. The abnormal methylation of CpG islands in the
promoter region of genes leads to a silencing of genetic
information and ﬁnally to alteration of biological function.
Emerging data suggest that these epigenetic modiﬁcations
also impact on the development of cardiovascular disease.
Histone modiﬁcations lead to the modulation of the
expression of genetic information through modiﬁcation of
DNA accessibility. In addition, RNA-based mechanisms
(e.g., microRNAs and long non-coding RNAs) inﬂuence
the development of disease. We here outline the recent
work pertaining to epigenetic changes in a cardiovascular
disease setting.
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Introduction
The term ‘‘epigenetics’’ refers to heritable changes in gene
expression, which are not a result of changes in the DNA
sequence, but rather due to alterations related to the
packaging (thereby altering DNA accessibility) and/or
translation of genetic information [6]. These changes are
mediated through complex environment/genome interac-
tions. Even though epigenetic variability of genetic infor-
mation is part of normal development and differentiation it
also underlies exogenous stimuli, e.g., smoking or drug
abuse, and as such may reﬂect the role of these factors on
the development of diseases. Important alterations
encompassing epigenetic changes are DNA methylation
and RNA-based mechanisms including those controlled by
microRNAs (miRNA) and long intergenic non-coding
RNAs (linc-RNA). These modiﬁcations result in a variable
expression of identical genetic information based on the
surrounding conditions leading to enhanced expression or
silencing of genes. The study of these alterations represents
a fascinating avenue to further elucidate the underlying
mechanisms of cardiovascular disease. This review pro-
vides an introduction to epigenetic mechanisms such as
DNA methylation, histone modiﬁcations and RNA-based
modiﬁcations as well as an outline of how these changes
pertain to the development of cardiovascular disease.
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In the mammalian genome the most widely appreciated
epigenetic modiﬁcation involves the covalent binding of a
methyl group, termed DNA methylation, to the 50-position
of cytosine residues in the so-called CpG (Cytosine pre-
ceding Guanosine) dinucleotides (see Fig. 1)[ 7]. CpG-
islands differ from the remainder of the genomic pattern in
that they are Cytosine-Guanosine-rich (CpG-rich) and
predominantly non-methylated [16]. CpG-islands have a
length of approximately 200–300 base pairs with a Cyto-
sine ? Guanosine (C ? G) content of about 50% and an
observed CpG/expected CpG in excess of 0.6. [22]. How-
ever, more recent analyses have shown that regions of
DNA with a length of more than 500 base pairs, including a
G ? C content of at least 55% and observed CpG/expected
CpG of 0.65 were more likely to be associated with the 50
regions of genes [71]. This deﬁnition excluded most Alu-
repetitive elements. Most CpG-Islands are sites of tran-
scription initiation. Due to the mutagenic properties of
methylcytosine vertebrate genomes are methylated pre-
dominantly at the dinucleotide CpG and are CpG-deﬁcient
[8]. A small fraction of cytosines (around 4%) are physi-
ologically methylated in the mammalian genome [21, 53].
DNA methylation plays an essential role in several
epigenetic phenomena including genomic imprinting,
X-chromosome inactivation and retro-element silencing
[42, 59, 79]. CpG dinucleotides are unequally distributed
across the human genome. Since vast stretches of sequen-
ces are deﬁcient for CpGs and are interspersed by CpG
clusters, these are also deﬁned as ‘‘CpG islands’’ (CpG-rich
areas). They are mainly associated with promoter regions
of genes (approximately 70% of gene promoters) and
mostly remain unmethylated [22, 53, 67, 71]. Cytosine
methylation is enzymatically driven by a transfer of a
methyl group from the methyl donor S-adenosylmethionine
to the carbon-5 position of cytosine [38]. DNA methylation
is, as currently known, catalyzed by at least three different
DNA methyltransferases (DNMTs): DNMT1, DNMT3a
and DNMT3b [11]. DNMT1 represents the main enzyme in
mammals. It serves a maintenance function (referred to as
maintenance methylation), since it is responsible for pos-
treplicative (during mitotic cell division) restoration of
hemi-methylated sites to full methylation [38]. Demethyl-
ation may occur after a reduction in DNMT-1 activity.
Recent evidence suggests that demethylation may also be
an active process [5]. However, this has not been proven in
the cardiovascular system. DNMT3a and DNMT3b are
implicated in de novo methylation (see Fig. 1)[ 80].
Methylation of cytosine in CpG islands is associated with
transcriptional repression by impeding the binding of tran-
scription factors to cis-DNA binding elements present in the
promoter regions of genes [80]. Recently, a family of
methyl-CpG binding proteins has also been recognized that
speciﬁcally bind to methylation marks, thereby contributing
totranscriptionalrepressionbyrecruitinghistone-modifying
proteins. These include the MBD protein family (MBD1,
MBD2, MBD4 and MeCP2), Kaiso and Kaiso-like proteins,
and SRA domain proteins (e.g., SUVH9 and SUVH2) [17].
Histone modiﬁcations
DNA within eukaryotic cells is condensed in chromatin.
The nucleosome is the core unit of chromatin and is
composed of an octamer of four different histones (H3, H4,
H2A, and H2B), around which DNA is wound with a
length of approximately 140–150 base pairs (see Fig. 2)
[37]. Histones are characterized by their large number and
diversity of modiﬁed residues [37]. Currently, at least eight
different types of modiﬁcations are known. These modiﬁ-
cations are catalyzed by distinct enzymes. These include
enzymes for methylation, acetylation, phosphorylation,
sumoylation, ubiquitination, ADP-ribosylation, deimina-
tion and proline isomerisation [37]. Histone modiﬁcations
serve the role of allotting the genome into ‘‘active’’ or
euchromatin, in which DNA is accessible for transcription,
Fig. 1 DNA methylation. Chromosome, histones and the DNA
double-helix including a CpG-rich DNA sequence is shown, where
the coupling of methyl groups is catalyzed by methyltransferases
(DNMT). These changes may also occur in response to exogenous
stimuli, e.g., smoking, cocaine abuse, arterial hypertension (examples
are given in the main text). DNMT-3a and -3b drive ‘‘de novo’’
methylation of genes, while DNMT-1 is associated with maintaining
the methylation state. Demethylation occurs after a reduction in
DNMT-1 activity. Recent evidence suggests that demethylation may
also be an active process (see [14])
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inaccessible for transcription [37].
RNA-based mechanisms
Recent high-throughput analyses of the transcriptome have
revealed that the genome transcribes *90% of genomic
DNA, of which only 1–2% encode for proteins, while the
majority are transcribed as non-coding RNAs [18]. There is
mounting evidence for the role of non-coding RNAs in the
regulation of development [23], in response to environ-
mental stress [20] and disease initiation/progression [81].
Current research efforts are therefore aimed at elucidating
the role of non-coding RNAs with respect to physiological
functions and diseases.
Non-coding RNAs are classiﬁed as infrastructural (small
nuclearandnucleolarRNAs,ribosomal RNAs)andregulatory
RNAs (microRNAs, long non-coding RNAs, Piwi-interacting
RNAs,smallinterferingRNAs).Weherewillfocusontherole
of two regulatory RNAs—microRNAs and long non-coding
RNAs—in the development of cardiovascular disease.
MicroRNAs
In the early 1990s Lee and co-workers were the ﬁrst to
describe a function for a speciﬁc miRNA, lin-4, during
postembryonicdevelopmentinthenematodeCaenorhabditis
elegans [39]. Since then, an array of miRNAs have been
discovered and analyzed. Currently, 851 different miRNAs
have been identiﬁed in humans, 793 in mice and 698 in rats
according to the MicroCosm Targets web resource [49]
(formerly miRBase Targets) developed by the Enright labo-
ratory at the European Bioinformatics Institute, Cambridge,
UK.However,the exactnumberof miRNAs within different
species is currently unknown.
MiRNAs lead to the repression of target genes through
the post-transcriptional degradation of messenger-RNA
and/or translational inhibition of protein expression [4].
Similar to mRNAs, primary miRNAs (pri-miRNAs) have a
50 7-methyl guanylate cap and 30 polyadenylated tail [12,
40]. After transcription of the pri-miRNAs by RNA poly-
merase II, the pri-miRNA, Drosha and the RNA-binding
protein DGCR8 complex is processed into a hairpin
structure, termed the precursor miRNA [26, 40, 41]. Via
binding to exportin 5 and Ran-GTP the precursor miRNA
is transported into the cytoplasm, where it is cleaved by
Dicer, and processed into a double-stranded product con-
sisting of 22 nucleotides. This mature miRNA consists of a
guide strand and a passenger strand. The miRNA guide
strand is incorporated into the RNA-induced silencing
complex (RISC) while the passenger strand is degraded.
The RISC–miRNA complex speciﬁcally targets mRNAs
and leads to negative regulation of protein synthesis or
mRNA degradation [1, 3, 77]. Using a ribosome proﬁling
strategy, it was recently shown that miRNAs predomi-
nantly act though destabilization of target mRNAs, which
subsequently leads to reduced protein output [27]. These
results show that destabilization of target mRNAs in
addition to translational inhibition may also be a mecha-
nism resulting in impaired protein production.
Currently, several groups have elucidated epigenetic
silencing of certain genes encoding microRNAs in the
cancer ﬁeld, thus fundamentally impacting on the expres-
sion of genetic information [2, 65]. The aim of the present
review was to underline the potential importance of this
mechanism in cardiovascular disease. We therefore dis-
cussed several important manuscripts dealing with epige-
netic silencing of microRNAs.
Long non-coding RNAs
By deﬁnition non-coding transcripts with a length [200
nucleotides are considered as long non-coding RNAs
(lncRNA) [63]. Depending on their position with regard to
protein coding genes lncRNA can be categorized as: (1)
sense or (2) antisense, (3) bidirectional, (4) intronic or (5)
intergenic [63]. LncRNAs are generally characterized by
nuclear localization, low level of expression and sequence
conservation and may be polyadenylated [36]. It was
Fig. 2 Histone modiﬁcations. Within the nucleus DNA is packaged
as chromatin in the nucleosome. It is composed of an octamer of four
different histones (H3, H4, H2A, H2B). Histones display a large
number of modiﬁed residues. Histone acetylation, methylation and
phosphorylation are shown as examples of histone modiﬁcations.
These modiﬁcations are catalyzed by distinct enzymes. Histone
modiﬁcations divide the genome into ‘‘active’’ or euchromatin, in
which DNA is accessible for transcription, and ‘‘inactive’’ or
heterochromatin, in which DNA is inaccessible for transcription.
Examples of how histone modiﬁcations may be altered in cardiovas-
cular (patho)physiology are shown. K lysine, S serine
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123recently shown that long intergenic non-coding RNAs
(lincRNAs) signiﬁcantly impact on the development of
human diseases [13, 33, 83]. LincRNAs control gene
expression by direct recruitment of histone modifying
enzymes to chromatin, regulate dosage compensation,
imprinting and developmental gene expression by estab-
lishing chromatin domains in an allele- and cell-type spe-
ciﬁc manner [63]. LincRNAs are characterized by
trimethylation of lysine 4 of histone H3 (H3K4me3) at
their promoter and trimethylation of lysine 36 of histone
H3 (H3K36me3) along the transcribed region [35]. Con-
trary to most lncRNAs, lincRNAs are higher conserved
between different species [35]. Long non-coding RNAs
play a critical role in the regulation of imprinting, exem-
pliﬁed by the lincRNA Air, and X-chromosome inactiva-
tion by Xist (X-inactive speciﬁc transcript) (see Fig. 3)
[63]. Xist through its co-factor RepA associates with the
polycomb complex and thereby initiates epigenetic
silencing during X-chromosome inactivation [84]. Air tar-
gets repressive histone-modifying activities through
molecular interaction with speciﬁc chromatin domains to
epigenetically silence transcription [55]. This illustrates a
ﬁrst example of how a lincRNA may impact on epigenetic
changes.
Epigenetic impact on cardiovascular development
Mathiyalagan and co-workers analyzed epigenetic modiﬁ-
cations on the speciﬁc gene expression during physiological
cardiovascular development. Increased ANP and BNP gene
expression in the left ventricle (LV) are associated with
increased histone acetylation and dimethylation. In addition,
increased a-MHC gene expression in the LV as compared to
the right ventricle (RV) was associated with H3K4 methyl-
ation. Chromatin immunopuriﬁcation conﬁrmed that the
histone acetyltransferase p300 is recruited and increased on
the active ANP and BNP genes in the left ventricle. The
authors concluded that cardiac chambers are thus epigeneti-
cally distinguishable [46].
Another example of epigenetic importance shows that
the loss of histone deacetylases 3 in neural crest results in
perinatal lethality and cardiovascular abnormalities. This is
associated with an impairment in aortic arch artery smooth
muscle differentiation and a downregulation of the Notch
ligand Jagged1 resulting in abnormalities of the cardiac
outﬂow tract [68].
Recently, the role of epigenetic modiﬁcations in the
regulation of vascular development has also come into
focus. Histone deacetylase 7 was shown to inﬂuence vas-
cular development through an alteration of the extracellular
matrix [45, 50]. The ﬂow-dependent regulation of gene
expression during vasculogenesis was shown to be inﬂu-
enced by HDACs modulating in vitro experiments
involving shear stress [34]. In addition, histone acetylation
is crucial for vascular gene expression in endothelial and
smooth muscle cells (SMC) [47, 69]. The histone acetyl-
transferase p300 signiﬁcantly impacts on the differentiation
of vascular SMCs underlining that chromatin remodeling is
important for SMC phenotypic switching [69].
Fig. 3 Long non-coding RNAs.
Long non-coding RNAs (non-
coding transcripts with a length
[200 nucleotides) comprise a
recently identiﬁed class of
chromatin-modiﬁers. These
RNAs play a critical role in the
regulation of several important
regulatory mechanisms
including X-chromosome
inactivation. During this process
Xist (X-inactive-speciﬁc
transcript) via its co-factor RepA
associates with the polycomb
complex and thereby initiates
epigenetic silencing. A role for
long non-coding RNAs in the
cardiovascular system is highly
likely, but so far unexplored.
Ezh2 enhancer of zest homolog
2, PRC2 polycomb repressive
complex 2, Suz12 suppressor of
zest 12, EED embryonic
ectodermal development
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Phenotypic alterations during adulthood may be explained
by exposure to adverse environmental conditions in utero.
Ground-breaking work elucidating this mechanism in
humans came from Heijmans and co-workers [29], who
studied individuals prenatally exposed to famine during the
Dutch Hunger Winter in 1944/45. Compared to siblings of
the same sex these individuals displayed an altered genetic
methylation pattern. DNA methylation of the imprinted
insulin-like growth factor II (IGF2) gene was shown to be
lower. The prevalence of obesity and coronary heart dis-
ease in these individuals was higher than that of adults born
before or conceived after that period [58]. Low birth
weight was shown to be an independent risk factor for
coronary heart disease [25]. These ﬁndings are corrobo-
rated by experimental studies, in which the critical impact
of maternal diet during pregnancy on the pattern of DNA
methylation of genes pertaining to blood pressure control
was shown [9].
The prenatal exposure to tobacco severely alters the
methylation pattern of speciﬁc genes and may increase the
risk of cardiovascular disease later in the child’s life. While
the methylation of the DNA repetitive element AluYb8 is
generally signiﬁcantly associated with prenatal tobacco
exposure, differences in smoking-related effects on LINE1
methylation are dependent upon a lack in a functional
detoxifying enzyme glutathione S-transferase P (GSTP1)
[10]. Thus, variants in detoxiﬁcation genes may modulate
the effects of in utero exposure through epigenetic
mechanisms.
In patients with end-stage heart failure differential DNA
methylation was shown to correlate with the gene expres-
sion of angiogenic factors, namely the PECAM1, ARH-
GAP24 and AMOTL2 gene [51].
Zhang and co-workers [85] demonstrated the detrimen-
tal effect of prenatal cocaine exposure regarding the
methylation status of speciﬁc genes. Cocaine exposure
induces a decrease in cardiac PKC-epsilon expression
through methylation of CpGs in the activator protein 1
(AP-1) binding site of the PKC-epsilon gene. Previous in
vitro and in vivo studies demonstrated that PKC-epsilon
has a critical cardioprotective role during cardiac ischemia
and reperfusion injury [14, 24, 32, 54]. The results of this
study indicate that prenatal cocaine abuse might alter the
cardiac response to ischemia reperfusion injury through
methylation of the AP-1 binding site and subsequent
repression of the PKC-epsilon gene. The PKC-epsilon gene
is also targeted during chronic prenatal hypoxia [61].
Chronic prenatal hypoxia leads to a decrease in PKC-
epsilon expression due to methylation of the speciﬁcity
protein 1 (SP1) binding sites in the PKC-epsilon promoter
in fetal hearts. Methylation of the SP1 site is gender-
speciﬁc with more males being affected. This difference is
most likely due to the higher abundance of estrogen
receptor alpha and beta isoforms found in females com-
pared to males, since both estrogen receptor alpha and beta
interact with the SP1 binding site in the fetal heart.
Histone methylation and cardiovascular disease
To further address the epigenetic response to cardiac
ischemia/reperfusion Das and co-workers [15] analyzed
caveolin knockout mice. Caveolins are an integral part of
lipid rafts, a sub-compartment of the plasma membrane.
Recent work suggests an important role for caveolins
during cardiac ischemia reperfusion injury [75]. Histone
methylation was shown to be increased and associated with
increased histone methyl-transferase G9a protein levels
and histone decaetylase activity in caveolin knockout mice
following ischemia reperfusion injury. In addition, the
translocation of Foxo-3a to the nucleus and expression of
sirtuin-1 was reduced in caveolin knockout mice. The
cardioprotective function of caveolins was further con-
ﬁrmed by reduced ventricular function, increased cardio-
myocyte apoptosis, increased expression of Janus kinase
and Bax and decreased expression of phospho-AMPK,
phospho-AKT and Bcl-2 in caveolin knockout mice. These
ﬁndings underline the importance of caveolins for cardio-
protection and their association with epigenetic mecha-
nisms during cardiac ischemia reperfusion injury.
Depending on the methylation of speciﬁc lysine or
arginine residues histone methylation can either be associ-
ated with transcriptional repression or activation [44, 66]. A
genome-wide histone methylation proﬁle revealed a dif-
ferential marking of trimethylation of H3K4 and H3K9
(H3K4me3 and H3K9me3) in cardiomyocytes during
development of heart failure in both animal models and
human [36]. Histone H3 lysine 4 methylation (H3K4me)
marks transcriptional activation [66]. Stein and co-workers
[70] recently analyzed the effect of reducing histone H3
lysine 4 methylation on differentiated cardiomyocytes.
PAX interacting protein 1 (PTIP) protein, an essential co-
factor of the H3K4me complex, was deleted through a
cardiac-speciﬁc, inducible knockout model. This resulted in
reduced H3K4me impacting on downstream signaling cas-
cades in cardiomyocytes. The gene encoding for Kv chan-
nel-interacting protein 2 (Kcnip2) was shown to be down-
regulated by trimethylation of lysine 4 of histone H3
(H3K4me3). Regulation of Kcnip2 resulted in several
impaired cellular functions, e.g., sodium and L-type cal-
cium current, action potential upstroke velocity as well as
enhanced action potential duration. PTIP mutant cardio-
myocytes were more sensitive to premature ventricular
complexes upon stimulation with isoproterenol and
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123caffeine. The results of this study clearly underline the
signiﬁcance of histone methylation for the physiological
function of cardiomyocytes.
To elucidate the role of H3K9 methylation on the
development of cardiac hypertrophy and failure Zhang
et al. [86] studied the involvement of the histone trimeth-
yllysine demethylase JMJD2A. JMJD2 proteins are lysine
trimethyl-speciﬁc histone demethylases that catalyze the
demethylation of trimethylated H3K9 (H3K9me3) and
H3K36 (H3K36me3) [86]. JMJD2A was shown to mediate
cardiac hypertrophy through regulation of its target FHL1
(four-and-a-half LIM domains 1). Zhang and co-workers
thus provide a novel mechanistic explanation for the epi-
genetic regulation of cardiac hypertrophy.
Recently, an epigenetic silencing of the endothelial
nitric oxide synthase (eNOS) promotor through methyla-
tion of the lysine residue 27 on histone 3 (H3K27me3) was
shown to control angiogenesis [57]. During hypoxia eNOS
expression was increased through reduction of repressive
H3K27me3. This reduction was associated with an increase
of the histone demethylase Jmjd3 (see Fig. 2).
Movassagh and co-workers [52] found the epigenomic
pattern in patients with end-stage heart failure to be highly
altered compared to control patients. Speciﬁcally, differ-
ential DNA methylation and trimethylation of lysine 36 of
histone 3 (H3K36me3) was found to be inﬂuenced in RNA
transcripts encoded by the DUX4 locus [68], which codes
for a double homeobox transcription factor and has been
implicated to play a role in facioscapulohumeral muscular
dystrophy [19, 62].
MicroRNAs and cardiovascular disease
MicroRNAs fundamentally are involved in and have impact
on cardiovascular disease. In addition, microRNA has been
shown to control cardiovascular differentiation [56]. An
arrayofstudieselucidatedadisease-speciﬁcroleforselected
miRNAs (for instance, miR-21 and miR-29 in cardiac
ﬁbrosis) [73, 78]. Moreover, microRNA signatures in total
peripheral blood have been identiﬁed as biomarkers of
myocardial infarction [48]. Deregulation of miRNAs results
in a profound disturbance ofdownstream gene networks and
signaling cascades culminating in disease initiation and/or
progression [74]. The role of miRNAs in the initiation of
cardiovascular disease has previously been reviewed (see
[28, 76]). Thus, the present review focuses on the epigenetic
regulation of microRNAs during pathophysiological pro-
cesses. We here outline DNA methylation of speciﬁc
miRNA genes and its impact on the expression levels of
miRNAs. This mechanism represents a fascinating novel
regulation of microRNA expression, which has not been
studiedincardiovasculardiseasesofar.Wethereforeshortly
mentionanddiscuss cancer-speciﬁc epigenetic regulationof
miRNA genes to spark interest in this new ﬁeld.
Several studies have addressed the effect of tumor-spe-
ciﬁc alterations in DNA methylation of miRNA genes on
the expression of mature miRNAs. Saito and co-workers
[65] evaluated the speciﬁc miRNA signature of T24 human
bladder cancer cells after simultaneous treatment with the
DNA methyltransferase inhibitor 5-aza-20-deoxycytidine
(DAC) and the histone deacetylase (HDAC) inhibitor
4-phenylbutyric acid (PBA). Genome-wide expression
analysis revealed that miR-127 was strongly up-regulated
following treatment with the chromatin-modifying drugs.
Importantly, the corresponding gene was found to be
embedded in a CpG island. MiR-127 is physiologically
expressed as part of a miRNA cluster with miR-136, -431,
-432, and -433 in normal tissues and cultured ﬁbroblasts. In
primary tumors and various cancer cell lines it is down-
regulated. Simultaneous treatment with the chromatin-
modifying drugs resulted in an induction of miR-127. The
results of this study suggest that it is subject to epigenetic
silencing. Its role in cardiovascular disease, e.g., ﬁbrosis,
remains to be elucidated.
The epigenetic regulation of miR-137 and its contribu-
tion to colorectal carcinogenesis was shown using several
colorectal cancer cell lines and colorectal tissues [2]. The
promoter region of miR-137 was identiﬁed to be exten-
sively methylated in cancer cell lines, which was reversible
following DAC treatment. The level of methylation was
signiﬁcantly higher in colorectal cancer tissues compared
with their corresponding histologically normal mucosa.
The expression of miR-137 in cancer tissue was signiﬁ-
cantly down-regulated. Over-expression of miR-137 in
cancer cell lines resulted in a signiﬁcant reduction of cell
proliferation. Lysine (K)-speciﬁc demethylase 1A (LSD1)
was identiﬁed as a target of miR-137 in colorectal cancer
cell lines using luciferase gene reporter assays. Thus, in
colorectal cancer miR-137 might act as a tumor suppressor.
During colon cancerogenesis it is frequently silenced by
promoter hypermethylation.
Currently, the epigenetic regulation of microRNA
expression through methylation of CpG islands in the
promoter region of genes encoding for speciﬁc microRNAs
has not been evaluated in the setting of cardiovascular
disease. The results of the aforementioned studies suggest
that this mechanism may also play a pivotal role in the
initiation of cardiovascular complications. Future studies
are warranted to address this phenomenon.
Long non-coding RNA and cardiovascular disease
The characterization of lncRNAs pertaining to the devel-
opment of cardiovascular disease is still in its infancy.
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holds enormous future promise given their regulatory
function in health and disease and there soon will be more
insight in this emerging topic.
In clear cell renal carcinoma, a natural antisense long
non-coding transcript (aHIF) that is complementary to the
30-untranslated region of hypoxia-inducible factor 1a (HIF-
1a) messenger RNA has been discovered [72]. It modulates
the stability of HIF-1a mRNA, thereby impacting on the
regulation of angiogenesis.
Robb and co-workers [64] discovered an antisense
transcript to endothelial nitric oxide synthase (eNOS),
termed sONE. RNA interference-mediated inhibition of
sONE expression in vascular smooth muscle cells
increased eNOS expression. Overexpression of sONE in
endothelial cells reduced eNOS expression. The antisense
lncRNA sONE might thus contribute to the post-tran-
scriptional regulation of endothelial cell-speciﬁc gene
expression.
Recently, an antisense long non-coding transcript to
tyrosine kinase containing immunoglobulin and epidermal
growth factor homology domain-1 (tie-1), tie-1AS, was
uncovered [43]. The tie-1AS lncRNA was shown to target
the tie-1 mRNA in vivo, thereby regulating tie-1 transcript
levels. This resulted in abnormalities in endothelial cell
contact junctions suggesting a role in the maintenance of
vascular homeostasis.
Single nucleotide polymorphisms (SNPs) on chromo-
some 9p21.3 near the INK4/ARF (CDKN2a/b) locus cor-
relate with susceptibility to cardiovascular disease [30, 31].
The SNPs most strongly associated with cardiovascular
disease are located *120 kb from the nearest coding gene
within a long non-coding RNA (ncRNA) known as ANRIL
(CDKN2BAS) [11]. ANRIL is an antisense non-coding
RNA in the INK4 Locus, which was ﬁrst discovered in a
genetic analysis of familial melanoma patients with neural
system tumors [60]. It recruits polycomb repressive com-
plexes to induce epigenetic transcriptional repression [82].
The identiﬁcation of altered expression patterns and func-
tion of individual lincRNAs will be a fascinating future
avenue to explore in the setting of numerous cardiovascular
diseases.
Conclusions
Epigenetic modiﬁcations such as DNA methylation, his-
tone modiﬁcations and RNA-based mechanisms represent
the molecular substrate for detrimental environmental
stimuli and may lead to disease initiation including car-
diovascular disease. Epigenetic changes may be targeted
and inﬂuenced in the future by pharmacological and/or
genetic interventions. For instance, the demethylating
agent 5-aza-20-deoxycytidine has been used in several
experimental studies [61, 65].
Additional studies are clearly needed to further elucidate
how epigenetic phenomena impact on the development of
cardiovascular disease. The number of studies on the role
of long non-coding RNAs and microRNAs, for which
methylated CpG islands have been identiﬁed, is presently
rather limited. However, studies pertaining to various
forms of cancer already suggest the major impact of these
processes on cellular homeostasis and the development of
disease. Manipulating the expression of long non-coding
RNAs and ‘‘methylated’’ microRNAs may thus represent
an interesting future therapeutic direction.
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